Ascentage Pharma’s olverembatinib gets China NMPA’s BTD to treat Philadelphia chromosome-positive acute lymphoblastic leukemia: Rockville Friday, March 7, 2025, 11:00 Hrs [IST ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

Zydus Lifesciences added 3.33% to Rs 917.10 after the company said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture generic Dasatinib ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced the launch of a dedicated sales ...

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...